Liver Volume Metrics to Predict Immunotherapy Outcomes in Unresectable HCC
Official title: Prediction of Immunotherapy Prognosis in Patients With Unresectable Hepatocellular Carcinoma Based on Functional Liver Volume and Total Liver Volume: A Multicenter Retrospective Cohort Study
Run by Anhui Provincial Hospital · NCT07782632 · Data updated 2026-11-12
This multicenter study tests whether baseline functional liver volume and total liver volume can forecast how patients with unresectable HCC respond to immunotherapy and how long they survive.
Quick facts
| Study type | Observational |
|---|---|
| Ages | 18 Years to 75 Years |
| Sex | All |
| Enrollment | 467 (estimated) |
| Sponsor | Anhui Provincial Hospital Government |
| Drugs / interventions | immunotherapy |
| Locations | 1 site (Hefei, Anhui) |
| Status | Recruiting |
| Started | January 1, 2019 |
| Main results expected | December 30, 2026 |
| Study ends | December 30, 2026 |
| Registry record updated | August 24, 2026 |
| Trial ID | NCT07782632 on ClinicalTrials.gov |
Is this trial a fit for you?
✓Likely a good fit
Adults (18+) with unresectable HCC who received immunotherapy and have high-quality baseline imaging plus complete follow-up data.
✕Probably not a fit
Patients lacking adequate imaging, incomplete records, or those with prior liver transplantation or concurrent malignancies may not benefit from this approach.
A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.
What this trial studies
This multicenter retrospective cohort analyzes pre-treatment imaging to measure functional and total liver volumes in adults with unresectable HCC treated with immunotherapy. Researchers will examine how these volumetric metrics relate to overall survival and progression-free survival using statistical analyses. The aim is to identify a simple, imaging-based way to help tailor treatment decisions. Data are drawn from multiple centers, focusing on patients with complete clinical and survival information. The study does not involve prospective intervention beyond measuring existing imaging data.
Why it matters
Potential benefit: If successful, baseline liver volume metrics could help clinicians predict which patients are more likely to benefit from immunotherapy and personalize treatment planning.
How similar studies have gone: Previous work has shown some prognostic value for imaging-derived liver metrics in liver cancer, but this multicenter validation in immunotherapy patients is relatively novel.
Who can join: the full rules
Show full inclusion / exclusion criteria
Inclusion Criteria: * Age \>= 18 years. * Clinically or histologically confirmed unresectable hepatocellular carcinoma (HCC). * Received immunotherapy as part of their tumor treatment regimen. * Availability of high-quality baseline pre-treatment imaging data suitable for functional liver volume and total liver volume segmentation. * Complete clinical and follow-up survival data. Exclusion Criteria: * \- Prior surgical resection or liver transplantation for HCC. * Co-existence of other concurrent primary malignant tumor types. * Severe image artifacts or technical limitations that prevent robust liver volume quantification. * Incomplete medical records, missing key baseline clinical data, or loss to follow-up.
Where it's running
-
The First Affiliated Hospital of University of Science and Technology of China
Hefei, Anhui, China Recruiting
Study contacts
- Study coordinator: Jizhou Wang, MD
- Email: wangjoe@ustc.edu.cn
- Phone: +86-551-62282931
Similar studies
Other studies for the same condition or treatment. Recruiting studies are listed first.
-
PULSAR radiotherapy plus immunotherapy for high-risk advanced liver cancer
This study tests whether adding PULSAR radiotherapy to standard immunotherapy helps adults with high‑risk advanced liver cancer live longer without their cancer progressing.
-
AI-guided treatment choices for advanced liver cancer
Researchers are testing an AI tool to help predict which patients with advanced hepatocellular carcinoma will respond to modern systemic therapies.
-
Intratumoral oncolytic virus plus immune checkpoint inhibitors in metastatic colorectal, gastric, or liver cancer
Doctors are testing whether injecting an oncolytic virus directly into tumors along with immune checkpoint drugs is safe and may help people with advanced colorectal, gastric, or liver cancer who have tried many treatments.
-
Biomarker testing to predict treatment response and recurrence in liver cancer
This study tests biomarkers in adults with hepatocellular carcinoma to see if they can predict how well treatments work and the chance of the cancer coming back.
-
MRI plus diffusion and CEST imaging to map liver cancer and its immune environment
This study tests whether adding an extra MRI sequence can help see how the liver cancer microenvironment changes and relate those changes to immune activity in patients with hepatocellular carcinoma.
-
Irreversible Electroporation Added to Targeted Therapy and Immunotherapy for Advanced HCC
This study tests whether adding irreversible electroporation to lenvatinib and sintilimab can help patients with unresectable advanced hepatocellular carcinoma see bigger tumor shrinkage and become eligible for surgery.
How to take part
- Review the eligibility criteria above with your treating physician.
- Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
- Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.